secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001171843-26-001506
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Filana Therapeutics reports 2025 net loss of $91M; cash burn guidance and TSC program clinical hold detailed
--------------------------------------------------------------------------------

- Net loss $91.0M ($1.88/share) vs $24.3M ($0.53) in 2024; cash $95.5M at Dec 31, 2025.
- Est. cash at June 30, 2026 at $47-50M; net cash use H1 2026 $14-17M plus $31.25M litigation settlement payment.
- R&D expenses fell 62% to $26.6M after Alzheimer's program phase-out; TSC program on clinical hold since Dec 2025.
- G&A expenses $68.8M include $31.3M securities litigation contingency; no insurance recoveries.
- Name change to Filana Therapeutics reflects focus on filamin A modulation for TSC-related epilepsy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184326001506/0001171843-26-001506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184326001506/f8k_031226.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-001506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer